NCT07042308 Natural History of Advanced Chronic Liver Diseases
| NCT ID | NCT07042308 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Cirrhosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-09-25 |
| Primary Completion | 2035-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2024-09-25 with a primary completion date of 2035-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a retrospective-prospective registry cohort study. Patients with advanced chronic liver disease (ACLD) will be prospectively invited to this study. The study follow-up duration will be 10 years. The primary outcome is incident hepatic events and liver-related mortality. Participants will undergo annual transient elastography examination.
Eligibility Criteria
Inclusion Criteria: * Aged 18 or above * Known ACLD, defined by: * LSM \> 10kPa or * Clinical cirrhosis, suggested by 1. ultrasonography of the hepatobiliary system shows features of cirrhosis (e.g. shrunken and nodular liver) and portal hypertension (e.g. dilated portal vein, portal-systemic collaterals or varices, splenomegaly, ascites). 2. Oesophagogastroduodenoscopy (OGD) shows presence of oesophageal varices (OV) and/or gastric varices (GV) and/or portal hypertensive gastropathy. Exclusion Criteria: * Current or past history of hepatocellular carcinoma (HCC) * History of liver transplantation * Asplenism or history of splenectomy * Serious medical illness with limited life expectancy of less than 6 months * Pregnancy * Unable to obtain or refusal of informed consent from patient
Contact & Investigator
Jimmy CT Lai, MB ChB
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT07042308 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07042308 currently recruiting?
Yes, NCT07042308 is actively recruiting participants. Contact the research team at jimmyctlai@cuhk.edu.hk for enrollment information.
Where is the NCT07042308 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT07042308 clinical trial?
NCT07042308 is sponsored by Chinese University of Hong Kong. The principal investigator is Jimmy CT Lai, MB ChB at Chinese University of Hong Kong. The trial plans to enroll 500 participants.